JP2024515064A - 新規方法 - Google Patents

新規方法 Download PDF

Info

Publication number
JP2024515064A
JP2024515064A JP2023561909A JP2023561909A JP2024515064A JP 2024515064 A JP2024515064 A JP 2024515064A JP 2023561909 A JP2023561909 A JP 2023561909A JP 2023561909 A JP2023561909 A JP 2023561909A JP 2024515064 A JP2024515064 A JP 2024515064A
Authority
JP
Japan
Prior art keywords
cells
feeder
composition
feeder cells
expanded
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023561909A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515064A5 (https=
Inventor
ジョン ハットン、アンドリュー
コヴァックス、イストヴァン
ヌスバウマー、オリヴァー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GammaDelta Therapeutics Ltd
Original Assignee
GammaDelta Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GammaDelta Therapeutics Ltd filed Critical GammaDelta Therapeutics Ltd
Publication of JP2024515064A publication Critical patent/JP2024515064A/ja
Publication of JP2024515064A5 publication Critical patent/JP2024515064A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2023561909A 2021-04-09 2022-04-08 新規方法 Pending JP2024515064A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2105113.1 2021-04-09
GBGB2105113.1A GB202105113D0 (en) 2021-04-09 2021-04-09 Novel method
PCT/GB2022/050886 WO2022214825A1 (en) 2021-04-09 2022-04-08 Novel method

Publications (2)

Publication Number Publication Date
JP2024515064A true JP2024515064A (ja) 2024-04-04
JP2024515064A5 JP2024515064A5 (https=) 2025-04-16

Family

ID=75949435

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023561909A Pending JP2024515064A (ja) 2021-04-09 2022-04-08 新規方法

Country Status (15)

Country Link
US (1) US20240197875A1 (https=)
EP (1) EP4320225A1 (https=)
JP (1) JP2024515064A (https=)
KR (1) KR20230167047A (https=)
CN (1) CN117222732A (https=)
AR (1) AR125325A1 (https=)
AU (1) AU2022254859A1 (https=)
BR (1) BR112023020584A2 (https=)
CA (1) CA3216225A1 (https=)
CO (1) CO2023015121A2 (https=)
GB (1) GB202105113D0 (https=)
IL (1) IL307395A (https=)
MX (1) MX2023011975A (https=)
TW (1) TW202305120A (https=)
WO (1) WO2022214825A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121532496A (zh) * 2023-07-20 2026-02-13 武田药品工业株式会社 用于制备γδT细胞的无网格方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016081518A2 (en) * 2014-11-17 2016-05-26 Adicet Bio, Inc. Engineered gamma delta t-cells
JP2018533373A (ja) * 2015-10-30 2018-11-15 キャンサー・リサーチ・テクノロジー・リミテッド 非造血組織常在性γδ Ｔ細胞の増幅および該細胞の使用
JP2020518289A (ja) * 2017-05-03 2020-06-25 キングス・カレッジ・ロンドン ガンマデルタｔ細胞の増幅、組成物およびその使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6028176A (en) 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
WO2007111714A2 (en) 2005-11-28 2007-10-04 Zymogenetics, Inc. Il-21 antagonists
CA2860170C (en) 2010-12-22 2022-06-14 The Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
RU2739770C2 (ru) 2014-06-11 2020-12-28 полибайосепт ГмбХ Экспансия лимфоцитов с использованием композиции цитокинов для активной клеточной иммунотерапии
KR20190098747A (ko) * 2016-12-05 2019-08-22 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 치료법을 위한 조작된 세포의 제조방법
CA3106056A1 (en) * 2018-07-26 2020-01-30 Ospedale Pediatrico Bambino Gesu (Opbg) Therapeutic preparations of gamma-delta t cells and natural killer cells and methods for manufacture and use
CN113423820A (zh) 2018-11-08 2021-09-21 伽马三角洲疗法有限公司 分离和扩增细胞的方法
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016081518A2 (en) * 2014-11-17 2016-05-26 Adicet Bio, Inc. Engineered gamma delta t-cells
JP2018533373A (ja) * 2015-10-30 2018-11-15 キャンサー・リサーチ・テクノロジー・リミテッド 非造血組織常在性γδ Ｔ細胞の増幅および該細胞の使用
JP2020518289A (ja) * 2017-05-03 2020-06-25 キングス・カレッジ・ロンドン ガンマデルタｔ細胞の増幅、組成物およびその使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LIN XIAO ET AL.: ""Large-scale expansion of Vγ9Vδ2 T cells with engineered K562 feeder cells in G-Rex vessels and t", CYTOTHERAPY, vol. 20, no. 3, JPN6026008460, March 2018 (2018-03-01), pages 420 - 435, ISSN: 0005808010 *
出口雅敏, 皮膚ΓΔT細胞レセプター陽性T細胞の増殖を促進するマウス線維芽細胞様皮膚間質細胞株のサイトカインMRNA発, JPN6026008459, 2008, ISSN: 0005808009 *

Also Published As

Publication number Publication date
CN117222732A (zh) 2023-12-12
TW202305120A (zh) 2023-02-01
CA3216225A1 (en) 2022-10-13
AU2022254859A1 (en) 2023-10-19
IL307395A (en) 2023-12-01
MX2023011975A (es) 2023-12-14
GB202105113D0 (en) 2021-05-26
AR125325A1 (es) 2023-07-05
KR20230167047A (ko) 2023-12-07
BR112023020584A2 (pt) 2023-12-05
US20240197875A1 (en) 2024-06-20
CO2023015121A2 (es) 2024-01-25
EP4320225A1 (en) 2024-02-14
WO2022214825A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
JP2023058687A (ja) ガンマデルタｔ細胞の増幅、組成物およびその使用
JP7665513B2 (ja) 細胞を単離及び拡大する方法
US10864259B2 (en) Methods and compositions for the treatment of melanoma
AU2017277499B2 (en) Compositions and methods for treating cancer
CN113766919B (zh) 制造抗bcma car t细胞
AU2019459423B2 (en) Anti-B7-H4 chimeric antigen receptor-modified NK-92 cells
JP7706361B2 (ja) 細胞を単離及び拡大する方法
EP1939278A1 (en) Method for production of t cell population
EP3833682A1 (en) Suicide module compositions and methods
KR20210057750A (ko) 암 면역치료요법을 위한 mr1 제한된 t 세포 수용체
KR20250018168A (ko) 막-결합된 il-15, cd8 폴리펩티드, 세포, 조성물, 및 이의 사용 방법
EP2028266A1 (en) Method of producing lymphocytes
US20110086367A1 (en) Pharmaceuticals for influencing the reaction of the human immune system
US20240197875A1 (en) Novel method
CN109641032B (zh) 用于治疗黑素瘤的方法和组合物
JP2023021361A (ja) メラノーマの処置のための方法および組成物
KR20200036874A (ko) 암 치료를 위한 방법 및 조성물
EP4624498A1 (en) Fusion polypeptide and use thereof
US20230374104A1 (en) Methods and compositions comprising pd1 chimeric polypeptides
CN121896167A (zh) 一种t细胞培养基、细胞培养物及其培养方法和应用
JP2026513951A (ja) 再発性または難治性の急性骨髄性白血病の処置に使用するためのｔ細胞
CN121568707A (zh) CAR-ThyTreg细胞、组合物及其在免疫疗法中的用途
IL298000A (en) Methods for isolating gamma delta t cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231027

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20231027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250408

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250408

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260303